Neurogranin (E9L8D) Rabbit mAb #79519
- WB
- IP
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 15 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Immunofluorescence (Frozen) | 1:200 - 1:800 |
Storage
For a carrier free (BSA and azide free) version of this product see product #85207.
Protocol
Specificity / Sensitivity
Neurogranin (E9L8D) Rabbit mAb recognizes endogenous levels of total neurogranin protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu17 of human neurogranin protein.
Background
Neurogranin is a small neuronal protein that binds to calmodulin in the absence of Ca2+ (1,2). Calmodulin binds Ca2+ and acts as a Ca2+ sensor to drive Ca2+-dependent signal transduction pathways by modulating its interaction with various kinases and phosphatases (3). In the postsynaptic compartment of the neuron, Ca2+ is carefully regulated and is a critical regulator of synaptic function and plasticity (4). Neurogranin is primarily expressed in the brain and is enriched in somato-dendritic compartments of projection neurons in various regions of the brain (5). Postsynaptically-enriched neurogranin likely influences Ca2+ or Ca2+/calmodulin-dependent neuronal functions, including synaptic plasticity, by binding to and releasing calmodulin in a Ca2+-dependent manner (6-9). Genetic variants in the gene encoding neurogranin, NRGN, are linked to several neuropsychiatric diseases, including schizophrenia (10). Interestingly, increase in cerebrospinal fluid neurogranin is correlated with neurodegenerative disease progression, which suggests that neurogranin could act as a biomarker for diseases like Alzheimer’s disease (11).
- Baudier, J. et al. (1991) J Biol Chem 266, 229-37.
- Gispen, W.H. et al. (1991) Mol Neurobiol 5, 61-85.
- Chin, D. and Means, A.R. (2000) Trends Cell Biol 10, 322-8.
- Blackstone, C. and Sheng, M. (2002) Front Biosci 7, d872-85.
- Gerendasy, D.D. and Sutcliffe, J.G. (1997) Mol Neurobiol 15, 131-63.
- Huang, K.P. et al. (2004) J Neurosci 24, 10660-9.
- Pak, J.H. et al. (2000) Proc Natl Acad Sci USA 97, 11232-7.
- Zhong, L. et al. (2009) EMBO J 28, 3027-39.
- Jones, K.J. et al. (2018) Proc Natl Acad Sci USA 115, E5805-E5814.
- Jin, L. et al. (2019) Medicine (Baltimore) 98, e18518.
- Willemse, E.A.J. et al. (2018) Clin Chem 64, 927-37.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.